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Introduction
Clinicians mostly do not treat all members of the ‘lipid family’ with the 
equal respect they deserve. Triglycerides often find themselves in the role 
of the neglected and ignored stepsister while all attention is lavished on 
the ‘evil’ sister, cholesterol. Triglyceride metabolism is, however, ignored 
at the clinician’s peril, as severe hypertriglyceridaemia can trigger 
potentially fatal acute pancreatitis. Less marked elevations of plasma 
triglycerides (TG) may also be deleterious by independently raising 
the risk for cardiovascular disease. Partially metabolised triglyceride-
rich lipoproteins (TGRL) (remnants) are among the most atherogenic 
lipoproteins. In addition, hypertriglyceridaemia often associates with other 
cardiovascular risk factors such as obesity, Type II diabetes, inflammation 
and a pro-thrombotic state.1,2 This article reviews hypertriglyceridaemia 
and focuses on severe hypertriglyceridaemia (TG > 10–15 mmol/L) and 
recent advances in the genetics of hypertriglyceridaemia. 
Being members of the ‘lipid family’, both cholesterol and TGs are 
insoluble in plasma and are packaged in lipoproteins for plasma export. 
Although lipoproteins may vary markedly in size and composition (e.g. 
from triglyceride-rich to cholesterol-rich), no lipoprotein exclusively 
transports a single lipid type. Triglyceride and cholesterol metabolism 
are thus intertwined and should not be considered separately, but 
viewed from the perspective of lipoprotein metabolism. 
Triglyceride-rich lipoprotein metabolism
Plasma TGs derive from two main sources: exogenous (uptake from 
dietary fat) and endogenous (hepatic synthesis). Following digestion 
and absorption, dietary fat is packaged into chylomicrons, which 
enter the circulation via the lymphatic system. Excess chylomicrons 
(hyperchylomicronaemia) cause turbid or even milky (lipaemia) plasma. 
Following a meal, up to 90% of plasma TGs are found in chylomicrons. 
The liver exports TGs (from endogenous synthesis or derived from 
uptake of chylomicrons) mainly as very low-density lipoproteins (VLDLs). 
In healthy individuals there should be no circulating chylomicrons 
following a 12-hour fast, and the bulk of TGs is found in VLDLs. VLDL 
particles may be subdivided into large, triglyceride-rich VLDL1 and 
smaller, less triglyceride-enriched VLDL2. Although triglyceride is the 
major lipid constituent of chylomicrons and VLDL, both these lipoproteins 
do contain cholesterol, and accumulation of TGRL may elevate the total 
cholesterol very substantially.
Chylomicrons are normally rapidly cleared from the circulation following 
partial hydrolysis of their triglyceride content by lipoprotein lipase (LPL), 
an enzyme found mainly in the capillaries of adipose and muscle tissue. 
The resulting chylomicron remnants are cleared from the circulation 
by hepatic uptake via apolipoproteinE (apoE) mediated binding. The 
triglyceride content of VLDL is also partially hydrolysed by LPL. The 
resultant VLDL-remnants can either be hepatically cleared via apoE or 
undergo further modification to form low-density lipoproteins (LDL). 
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LPL activity is regulated at multiple levels. At the genetic level, 
peroxisome proliferator-activated receptor γ (PPARγ) upregulates 
adipose tissue LPL, while liver LPL is upregulated by PPARα and liver 
X receptor (LXR). Exercising increases skeletal muscle LPL expression. 
The enzymatic activity of LPL is increased by apolipoproteinCII (apoCII) 
(essential cofactor) and apolipoproteinAV (apoAV), while apolipoproteinCIII 
(apoCIII) inhibits LPL.3 Recent research has led to the identification of 
multiple other proteins involved in the lipolytic process. These include 
two members of the angiopoetin-like protein family (ANGPLT), namely 
ANGPLT3 and ANGPLT4. ANGPLT3 inhibits LPL catalytic activity in 
the presence of substrate while ANGPLT4 inhibits LPL activity by 
promoting the conversion of active LPL dimers into inactive monomers.4 
Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding 
protein 1 (GPI-HBP1) is a high-affinity anchor for LPL.4
Increased plasma TGRL can therefore mechanistically result from 
increased production (increased hepatic synthesis, high-fat diets) 
or reduced clearance (mainly decreased LPL activity or occasionally 
dysfunctional apoE). In many patients hypertriglyceridaemia is 
multifactorial with both mechanisms contributing to accumulation of 
TGRL. Plasma TGs can fluctuate widely and rapidly. Dietary indiscretions 
(fatty meals) or metabolic stressors (e.g. uncontrolled diabetes mellitus) 
can rapidly raise plasma TGs, converting moderate hypertriglyceridaemia 
into severe hypertriglyceridaemia (see Box 1 for an example). 
Classification
There is no uniform classification system for hypertriglyceridaemia. 
A frequently used classification is: primary hypertriglyceridaemia 
(molecular aberration of lipoprotein metabolism, no other metabolic 
abnormalities) or secondary hypertriglyceridaemia due to metabolic 
precipitants. This classification is somewhat simplistic, as many patients 
with secondary hypertriglyceridaemia are likely to have ‘susceptibility 
genes’, as equivalent metabolic stressors provoke very variable 
individual triglyceride responses (see below). In most patients, including 
those with primary hypertriglyceridaemia, the molecular cause remains 
unknown.5
Hypertriglyceridaemia can also simply be classified according to 
the degree of triglyceride elevation: TG < 1.7 mmol/l is regarded 
as normal (2.3 mmol/L in some classifications), TG < 5.0 mmol/L 
is mild hypertriglyceridaemia, TG 5–10 mmol/L is moderately 
severe hypertriglyceridaemia and TG > 10 mmol/L is very severe 
hypertriglyceridaemia. 
The Fredrickson classification of hyperlipidaemia6 is also widely used, 
but often poorly understood – leading to much confusion. Fredrickson 
simply grouped similar agarose electrophoresis patterns and labelled 
them with Roman numerals. The intention was not to create an 
aetiological classification but to group electrophoretic patterns. Further 
details regarding the Fredrickson classification can be found in Table 
I. As our knowledge of lipoprotein metabolism and its disorders grew, 
some electrophoretic patterns were found to be characteristic of 
molecularly defined disorders (e.g. Type I pattern → LPL deficiency), 
while other patterns have no specific molecular correlates (e.g. Type 
IIa). Yet other molecularly defined disorders have variable patterns such 
as dysbetalipoproteinaemia (apoE mutations) – the Type III pattern is 
characteristic but the electrophoresis may also variably be classified as a 
Type IIb, Type IV or even Type V pattern. The conflation of electrophoretic 
patterns and metabolic and genetic diagnoses are responsible for much 
of the confusion surrounding the Fredrickson classification. 
Genetics of hypertriglyceridaemia
Monogenic disorders
Homozygous mutations in LPL cause severe primary hypertriglyceridaemia 
from birth. The clinical phenotype is characterised by eruptive xanthomata, 
hepatosplenomegaly and lipaemic plasma. Pancreatitis may occur in 
infancy. The agarose electrophoresis is characterised by an accumulation 
of chylomicrons (Fredrickson Type I pattern), and LPL deficiency is thus 
often also known as Type I hyperlipidaemia. LPL deficiency is a rare 
condition, but in South Africa there are founder mutations in the Indian 
and Afrikaner populations. Cases have, however, been reported from all 
population groups. 7 As this is a recessive disorder, there is usually no 
family history of hypertriglyceridaemia. LPL deficiency is a potentially fatal 
disorder and all children with hypertriglyceridaemia should be referred 
for urgent specialist evaluation. Establishing the correct diagnosis is 
essential in planning management. The University of Cape Town’s Lipid 
Laboratory can estimate lipolytic activity and screen for the common 
founder mutations in LPL. Currently, the only available management is 
dietary, with severe restriction of dietary TGs. The implementation of a 
very low-fat diet, while still providing adequate calories and essential 
fatty acids for growth and nutrition, requires advice from a dietitian 
specialised in lipid disorders and is especially challenging in infants. 
Lipid-lowering drugs are ineffective but are still frequently prescribed 
inappropriately, especially when an exact diagnosis has not been made. 
Gene therapy may be a therapeutic option in the future. Early Phase I 
human trials using adeno-associated virus as a vector to express an LPL 
allele with enhanced catalytic activity in muscles have been completed 
in humans with encouraging short-term results.8,9
Although heterozygous mutations in LPL reduce measured lipolytic 
activity, most carriers have normal lipid phenotypes. In situations of 
metabolic stress or in the presence of mutations or polymorphisms in 
other genes involved in lipid metabolism, hypertriglyceridaemia, usually 
of mild to moderate severity, may manifest. The Fredrickson pattern is 
variable, with Type IV and Type V patterns being the most common. In a 
Assumptions:
• Complete digestion and absorption of dietary fat
• Clearance is zero (e.g. LPL deficiency)
• Ignore VLDL production
• Fasting triglycerides are 4 mmol/L
• Plasma volume of 3 L
• 1 mol triglycerides ≈ 885 g
  Take-away meal: Triglyceride content
• Double hamburger with cheese 42 g
• French fries (large) 30 g
• Chocolate triple thick shake (supersize) 28 g
Total meal is 100 g of triglyceride → 113 mmol 
Change in triglycerides: 113 mmol of triglyceride / 3 L plasma volume: 37.66 mmol/L
Triglycerides can rise from 4 mmol/L to over 40 mmol/L
Cholesterol consumed: 255 mg (≈ 0.7 mmol) 
Box 1: Triglyceride response to a fatty meal
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recent report, the entire LPL, apoCII and apoAV genes were sequenced 
in 110 non-diabetic patients with TG >10 mmol/L (Fredrickson Type V 
pattern) on at least two occasions. Known disease-causing mutations in 
LPL were identified in seven patients, indicating that heterozygous LPL 
mutations may be an important contributory factor in some patients with 
adult-onset severe hypertriglyceridaemia.5
ApoCII activates LPL, and homozygous apoCII deficiency is phenotypically 
indistinguishable from LPL deficiency.10–13 Fresh frozen plasma contains 
apoCII and may be infused at times of severe hypertriglyceridaemia or 
when pancreatitis has developed. To the best of my knowledge, there 
are no known cases of apoCII deficiency in South Africa. 
Dysbetalipoproteinaemia (also known as Fredrickson Type III 
hyperlipidaemia or remnant removal disease) is characterised by the 
accumulation of remnants of TGRL. The most common molecular cause 
is homozygosity for the receptor-binding defective ε2 isoform of apoE.14 
Phenotypic expression of the disease usually requires the presence of 
additional metabolic stressors such as diabetes, obesity or hypothyroidism. 
Patients typically present with severe mixed hyperlipidaemia (molar ratio 
of total cholesterol to plasma TGs approximates 2 : 1.) and high levels 
of apoE.15 Severe hypertriglyceridaemia, however, is not infrequent 
and high levels of apoE2 have been shown to impair lipolytic activity 
mainly by displacing or masking apoCII.16 Polymorphisms in apoAV 
may also explain why hypertriglyceridaemia is more severe in some 
dysbetalipoproteinaemic patients.17 
More recently, mutations in several novel genes have been identified 
as causes of severe hypertriglyceridaemia. Some of these genes are 
listed below. 
• ApoAV is encoded on chromosome 11, and homozygosity 
for rare truncating mutations in ApoAV (Q139X) may cause 
hyperchylomicronaemia.18,19 In the majority of patients, 
hypertriglyceridaemia was first documented in adulthood. The 
molecular mechanism of hypertriglyceridaemia in apoAV deficiency 
is not well understood, but may include failure to inhibit hepatic 
VLDL-triglyceride production as well as impaired lipolysis due 
to LPL not having adequate access to the lipoprotein core in the 
absence of functional apoAV.20 The genotype is not fully penetrant 
and not all mutation carriers have hypertriglyceridaemia. 
• Lipase maturation factor (LMF 1) is involved in the endoplasmic 
maturation of LPL and hepatic lipase peptides. Homozygous 
nonsense mutations in LMF 1 have been identified in a few patients 
with severe hypertriglyceridaemia.21,22 
• GPI-HBP1 is an endothelial cell surface protein found in the 
capillaries of organs where lipolysis occurs. GPI-HBP1 likely 
provides a platform for lipolysis to occur by anchoring LPL, TGRL 
and apoAV-phospholipid disks.23 Homozygous mutations in this 
protein have been identified in several patients with severe 
hypertriglyceridaemia in whom other known genetic causes of 
hypertriglyceridaemia had previously been excluded.24,25 
The term familial hypertriglyceridaemia (FHTG) is often used to describe 
inheritance of a lipid phenotype characterised by an isolated increase in 
VLDL (Fredrickson Type IV pattern) – often with concomitantly low high-
density lipoprotein cholesterol (HDLC). Most patients with FHTG have 
moderate elevations in TGs in the 3 to 10 mmol/L range. The disorder 
is familial but the molecular basis is unknown and is likely polygenic 
in many patients (see below).26 FHTG is often found in association with 
other cardiovascular risk factors such as obesity, insulin resistance, 
hypertension and hyperuricaemia and overlaps with the metabolic 
syndrome. In future, the clinically described entity of FHTG is likely to be 
progressively replaced by a multiplicity of molecularly diverse disorders 
with similar lipid phenotypes. 
Familial combined hyperlipidaemia (FCH) is inherited in an autosomal 
dominant fashion with variable penetrance.27 The population frequency 
is reported to be 2 to 5%, making it the most common genetic 
dyslipidaemia. The lipid phenotype may vary widely within families, 
ranging from phenotypes dominated by increases in VLDL to those 
in which increased LDL is the major abnormality. HDLC is often low 
and apoB levels are usually high. Atherosclerotic risk is high. Severe 
hypertriglyceridaemia is uncommon in FCH and TGs are usually less 
than 5 mmol/L. The diagnosis is clinical and requires knowledge of the 
family history and lipid values in family members.28 The genetics of FCH 
have not been fully elucidated and it is likely that FCH is a genetically 
heterogeneous disorder. FCH has been linked to the APOAI/CIII/AIV/AV 
gene cluster,29 but the strongest candidate gene currently is Upstream 
Stimulatory Factor 1 (USF1), which encodes a transcription factor that 
modulates the expression of many genes involved in lipid and glucose 
homeostasis.30,31 Mutations in USF 1 may result in defective insulin-
mediated induction of USF 1 and subsequently reduced expression of 
target genes.32 
Polygenic hypertriglyceridaemia
In the majority of patients, the genetic basis of hypertriglyceridaemia 
remains unknown. Genome-wide association studies (GWAS) are 
improving our understanding of the genetic architecture of complex 
diseases. Single nucleotide polymorphisms (SNPs) at many loci have 
been linked to triglyceride metabolism in healthy controls, although the 
absolute effect on triglyceride levels is generally very small.33 In a recent 
study of hypertriglyceridaemic patients, previously identified SNPs were 
found to cluster according to Fredrickson phenotype. SNPs in ApoAV, 
Transducin-beta-like-2 (TBL2 – function unknown) and homologue 
of Drosophila Tribbles 1 (TR1B1 – function unknown) significantly 
associated with Fredrickson IIB, III, IV and V phenotypes. SNPs in other 
Table I: Agarose gel electrophoretic patterns according to Fredrickson’s classification
Pattern Predominant stain/band Lipoprotein predominantly increased Comments
Type I Origin Chylomicrons LPL + apo CII deficiency
Type II A Beta-band LDL
TG > 2.3 mmol/L distinguishes IIA from IIB
Type II B Beta-band and pre-beta-band LDL and some VLDL
Type III Broad-beta band Remnant particles
Broad beta describes uniform staining from beta 
to pre-beta
Type IV Pre-beta band VLDL
Type V Origin + pre-beta band Chylomicrons + VLDL
Legend: Lipoproteins migrate as follows from origin: origin (chylomicrons), beta-band (LDL), pre-beta band (VLDL) and alpha-band (HDL). The Fredrickson’s classification does not comment on HDL staining.
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genes, including ANGPTL3 and apoE, associated with selected phenotypes 
only.17 Taken together, these genotypes explained about 20% of variation 
in triglyceride concentration. Direct sequencing of some of these genes 
linked to hypertriglyceridaemia by GWAS but of as yet unknown function 
may identify rare loss of function mutations and provide a monogenic 
explanation for some patients with severe hypertriglyceridaemia. Clearly, 
our understanding of triglyceride metabolism is not yet complete. A 
plausible genetic model for hypertriglyceridaemia is that rare loss of 
function mutations with large effect sizes (e.g. LPL mutations) are found 
in a small group of patients, usually with extreme phenotypes. In most 
other patients, hypertriglyceridaemia may result from accumulating 
multiple common alleles that each individually only have a minor effect 
on triglyceride metabolism. Such a genetic background would not 
necessarily lead to hypertriglyceridaemia in itself, but would markedly 
increase the likelihood of hypertriglyceridaemia developing with 
environmental or metabolic stressors. 
Secondary causes of hypertriglyceridaemia
Metabolic stressors or exposure to certain drugs may lead to 
hypertriglyceridaemia in some but not all patients. Those that develop 
hypertriglyceridaemia are likely genetically predisposed (see above), 
although we do not fully understand the interactions between the 
genome and the environment as yet. In clinical practice, diabetes is the 
most common metabolic stressor. In susceptible individuals certain drugs 
can also trigger hypertriglyceridaemia. Further information on secondary 
causes of hypertriglyceridaemia can be found in Tables II and III. 
Clinical manifestations
Physical signs
Eruptive xanthomata (Figure 1) are cutaneous manifestations of severe 
hypertriglyceridaemia regardless of aetiology. They are small yellow 
papules often on an erythematous base. They tend to occur in crops 
Table II: Secondary causes of hypertriglyceridaemia
Condition Comments
Obesity 
Mild hypertriglyceridaemia frequent in metabolic syndrome
Increased waist circumference highly predictive of mild 
hypertriglyceridaemia
Diet
See Box 1 for the effect of dietary fat in patients with 
lipolytic defects
Diabetes mellitus
Most common secondary cause in our experience
Controlling diabetes mellitus often lowers TGs substantially
Alcohol 
Alcohol can increase VLDL synthesis
Pancreatitis risk from alcohol and TGs
Renal disease Mild hypertriglyceridaemia frequently seen in uremia
Pregnancy
Increased VLDL production may expose lipolytic effect
Pancreatitis has high fatality rate in pregnancy
Paraproteins May inhibit lipolytic proteins
Autoimmune disorders
Systemic lupus erythematosus (SLE) may generate  
auto-antibodies to LPL
Other disorders
Glycogen storage disorders may have mild  
hypertriglyceridaemia
Figure 1: Eruptive xanthomata
Legend: Eruptive xanthomata occur in hyperchylomicronaemia and are usually asymptomatic. 
They indicate severe hypertriglyceridaemia and a high risk of acute pancreatitis. Eruptive 
xanthomata tend to occur in crops on the elbows, knees, thighs, buttocks and trunk.
Figure 2: Lipaemic plasma
Legend: Plasma that has stood overnight at 4 °C appears milky and turbid. Chylomicrons have 
floated to the top and have formed a creamy layer. 
Figure 3: Tuboeruptive xanthomata
Legend: Tuboeruptive xanthomata may occur with long-standing hyperchylomicronaemia but 
are most commonly seen in severe mixed hyperlipidaemia such as dysbetalipoproteinaemia. 
Table III: Drugs associated with hypertriglyceridaemia
Drug Comments
Oestrogen
Oral oestrogen elevate TGs more than transdermal 
preparations
May cause marked hypertriglyceridaemia in  
susceptible individuals
Corticosteroids




Check baseline TGs before therapy and once on 
treatment
Antiretrovirals





Avoid prescription when TGs are increased
Immunosuppressant drugs Sirolimus frequently implicated
Beta blockers, thiazides Increase in TGs usually minor
Atypical antipsychotics
Weight gain, insulin resistance and diabetes  
commonly accompany rise in TGs
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and are most commonly found on the extensor surfaces of elbows and 
knees, the buttocks, thighs and trunk. Eruptive xanthomata resolve over 
several weeks to months once the TGs have been controlled. The retina 
may appear pink with ‘milky’ vessels in severely hypertriglyceridaemic 
patients – this is known as lipaemia retinalis. Plasma that has been left 
standing overnight at 4 °C (Figure 2) appears turbid (VLDL excess) with 
a creamy layer on top (chylomicron excess). In long-standing, severe 
hypertriglyceridaemia or in patients with dysbetalipoproteinaemia, 
eruptive xanthomata may coalesce to form tuboeruptive xanthomata 
(Figure 3). 
Pancreatitis
Severe hypertriglyceridaemia is a well-established trigger for acute 
pancreatitis.34,35. Accurate measurement of serum amylase is challenging 
in the presence of lipaemia, and pancreatitis may be falsely ruled out 
when the amylase is not elevated.36 Pancreatitis rarely occurs when TGs 
are under 10 to 15 mmol/L. In many patients, TGs are only measured 
several days after the onset of pancreatitis and a prolonged period of nil 
per mouth. In such situations, hypertriglyceridaemia may have improved 
markedly and may then be erroneously excluded as a possible cause 
of pancreatitis. As illustrated in Box 1, TGs may vary markedly and 
rapidly and a patient with only moderately elevated TGs may develop 
pancreatitis following a short period of dietary indiscretion. However, 
there are also patients with persistently marked hypertriglyceridaemia 
who never develop pancreatitis. Pancreatitis is therefore an 
unpredictable complication of hypertriglyceridaemia that strikes 
unexpectedly. The pathophysiology of hypertriglyceridaemic pancreatitis 
remains imperfectly understood. Intravascular triglyceride hydrolysis by 
pancreatic lipase with subsequent release of free fatty acids is the most 
commonly postulated pathophysiological mechanism.35 
The treatment of hypertriglyceridaemic pancreatitis does not differ 
fundamentally from that of pancreatitis of any other cause. Metabolic 
disturbances should be sought and controlled. Should total parenteral 
nutrition be necessary, it is important to avoid excess fat supply (e.g. 
Intralipid or Lipovenous). Subsequently, severe restriction of dietary fat 
intake is necessary. Apheresis will rapidly, but transiently, lower plasma 
TGs.34,37 There is no evidence that patients treated with apheresis recover 
more rapidly or have fewer pancreatitis-associated complications, and 
this expensive treatment modality cannot be routinely recommended.38 
Atherosclerosis
Moderate hypertriglyceridaemia is an independent risk factor for 
atherosclerosis, and TGs have been incorporated in the PROCAM 
cardiovascular risk-prediction algorithm.39,40 Subsequent studies have 
confirmed these findings41 and also suggest that non-fasting TGs are a 
better predictor of risk than fasting TGs.42,43 Non-fasting TGs probably 
predict risk better than fasting TGs, as they, at least in part, reflect the 
duration of postprandial lipaemia and the rapidity with which atherogenic 
remnant lipoproteins are cleared. It is, however, almost impossible to 
precisely determine the contribution that moderate hypertriglyceridaemia 
makes to cardiovascular risk independently due to the multiple metabolic 
abnormalities (diabetes, obesity, hypertension), secondary lipid changes 
(low HDLC, small dense LDLC) and pro-inflammatory and pro-thrombotic 
changes seen in association with hypertriglyceridaemia. 
Treatment of hypertriglyceridaemia
Treatment to reduce cardiovascular risk 
The evidence base for specifically targeting mild to moderate 
hypertriglyceridaemia beyond control of other risk factors, including 
LDLC, in patients at high cardiovascular risk is limited. Most clinical 
outcome studies have focused on LDLC reduction as the primary target 
and have used statins that have modest triglyceride-lowering properties. 
The strongest evidence of benefit for a non-LDLC-centred strategy 
comes from studies in which fibrates were given to patients with well-
defined lipid phenotypes: moderate hypertriglyceridaemia with low 
HDLC.44,45 The ACCORD study is currently investigating the use of a statin 
versus a statin + fibrate strategy in high-risk Type II diabetes mellitus. 
There are no well-established triglyceride target values and treatment 
selection currently requires careful analysis of the lipid phenotype as 
well as a lifestyle review and clinical judgement. A fuller discussion of 
these issues can be found in Yuan et al46 and Brunzell.47
Treatment of severe hypertriglyceridaemia 
The primary goal is to lower TGs rapidly to reduce the risk of acute 
pancreatitis. Cardiovascular risk reduction is of secondary concern, but 
becomes increasingly relevant once the pancreatitis risk has been dealt 
with. 
Non-drug treatment
Secondary factors that may be contributing to hypertriglyceridaemia 
need to be actively sought out and treated (Tables II and III). In 
clinical practice, the most common problem is either undiagnosed or 
uncontrolled diabetes. Admission to hospital is often helpful to rapidly 
control hyperglycaemia. If drugs are contributing significantly to 
hypertriglyceridaemia, treatment should be switched or discontinued 
if the patient’s clinical condition allows this and there are effective 
alternative treatment options. In the longer term, weight loss and 
exercise contribute to improved metabolic control. 
Marked restriction of dietary fat intake is essential when managing 
severe hypertriglyceridaemia (see Box 1). At Groote Schuur Hospital we 
prescribe an extremely low-fat diet (less than 10 g of fat a day [g/d]) for 
about three days when patients with severe hypertriglyceridaemia are 
initially referred. This diet is colloquially known as the ‘Rescue diet’ and 
rapidly lowers TGs (Box 2). It is not nutritionally adequate in the long term 
and the long-term dietary goal is to restrict total fat intake to around 
20–30 g/d. This is not always easy to achieve and requires dedication 
from the patient (reading labels, assessing portion sizes, calculating 
expenditure on ‘fat budget’) and the assistance of a dietitian with specific 
experience in the management of severe hypertriglyceridaemia. Dietary 
fat restriction needs constant re-enforcement and spiking triglyceride 
values on follow-up are often related to dietary indiscretions. Alcohol 
should ideally be avoided completely or intake should be reduced 
drastically. 
Omega-3 fatty acids (fish oils) lower TGs by reducing the synthesis 
and secretion of VLDL48 and by increasing expression of LPL in adipose 
tissue.49 Pharmacological doses of around 4 g/d of eicosapentaenoic acid 
(EPA) and docosahexaenoic acid (DHA) are required for maximal effect. 
Fish oils are most effective in moderately severe hypertriglyceridaemia 
and may lower TGs by up to 40% in some patients.50,51 Fish oils are 
ineffective in LPL deficiency and related disorders and may worsen 
hypertriglyceridaemia if prescribed inappropriately. Preparations of 
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sufficient strength and purity are not always readily available in South 
Africa.
Drug treatment
Monotherapy is preferred initially, but many patients do ultimately 
require combination lipid-lowering therapy to achieve optimal control. 
Combination therapy should be prescribed with due consideration of 
contra-indications and with careful monitoring. The second drug is 
selected based on the predominant remaining lipid abnormality once a 
steady state has been reached on monotherapy. 
Fibric acid derivatives include bezafibrate, fenofibrate and gemfibrozil. 
These drugs influence lipid metabolism at multiple points by binding to 
PPAR-α in the liver and modulating transcription of many genes involved 
in lipoprotein metabolism. Fibrates are central to the management of 
severe hypertriglyceridaemia and are the drugs of first choice. Fibrates 
lower TGs, increase HDLC and may either lower or in some cases raise 
LDLC. The latter situation often arises in hypertriglyceridaemic subjects 
when the more efficient lipolytic processing brought about by fibrates 
results in increased LDL production. Fibrates are excreted renally and 
doses need to be adjusted to renal function. Fibrate therapy is often 
accompanied by a modest (± 10%) rise in creatinine but this is not due to 
a lowered glomerular filtration rate and reverses on discontinuation.52,53 
Niacin may lower TGs by up to 45% but is most frequently prescribed 
in mild to moderate hypertriglyceridaemia. There are multiple other 
beneficial effects on the lipid profile (LDLC reduction, HDLC increase, 
Lp(a) reduction) and niacin prescription is generally targeted at 
cardiovascular risk reduction rather than the management of severe 
hypertriglyceridaemia. Flushing and pruritus limit the acceptability to 
patients but newer preparations with reduced flushing due to slow-
release formulation and the addition of a prostaglandin D2 receptor 
1 blocker should be available in South Africa soon.54
Statins do lower TGs but are not effective in severe hypertriglyceridaemia. 
In the experience of the Groote Schuur Hospital’s lipid clinic, statins 
continue to be frequently prescribed for severe hypertriglyceridaemia with 
predictably disappointing results. Statins may be used as monotherapy 
in mild to moderate hypertriglyceridaemia or in combination with fibrates 
if LDLC remains high after TGs have been controlled. 
Ezetimibe does not lower TGs significantly but can be combined with 
fibrates if additional LDLC lowering is required and statins are contra-
indicated or not tolerated. Cholestyramine can raise TGs and should be 
avoided in hypertriglyceridaemia. 
Conclusion
Marked hypertriglyceridaemia is a risk factor for pancreatitis, while 
moderate hypertriglyceridaemia is a cardiovascular risk factor. Several 
new proteins that play important roles in lipolysis have been discovered 
recently and GWAS have identified linkages to many genes of as yet 
unknown function. We may yet have a lot to learn about lipolysis and 
TGRL metabolism in general. 
The case for treating severe hypertriglyceridaemia is unequivocal, while 
treatment strategies and triglyceride goals are less well defined in 
moderate hypertriglyceridaemia, where the focus is on cardiovascular 
risk reduction. 
Although LDL rightly remains the focus of our attention for cardiovascular 
risk reduction and the belle of the ball, TGRL are attracting increasing 
scientific attention and study. Unfortunately, this is not a true fairytale 
transformation, as the emerging Cinderella certainly has a mean and 
vindictive streak, causing mayhem in the pancreas or partnering with 
her stepsister to ravage the arteries. 
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